X

Drug Profile

AVT 02

Alternative Names: AVT-02 UE

Latest Information Update: 31 Mar 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Gottingen
Developer DOLTHERA
Class Anti-inflammatories; Antipsoriatics; Oligonucleotides
Mechanism of Action STAT1 transcription factor inhibitors; STAT3 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Psoriasis

Most Recent Events

31 Mar 2011 Discontinued - Phase-II for Psoriasis in Europe (Topical)
06 Jan 2010 AnGes MG terminates its licence for AVT 02 in respiratory and dermal indications in Asia
10 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Psoriasis released by Avontec

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com